Hypogonadism, testosterone, and nursing home residents

Journal of the American Medical Directors Association

Volumn 14, Issue 6, 2013, Pages 381-383

  Morley, John E ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOSTERONE; VITAMIN D;

COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; EDITORIAL; HEART FAILURE; HEMATOCRIT; HUMAN; HYPOGONADISM; MEDICAL LITERATURE; MEN'S HEALTH; MILD COGNITIVE IMPAIRMENT; MORTALITY; MUSCLE MASS; MUSCLE STRENGTH; NURSING HOME; NURSING HOME PATIENT; WATER RETENTION;

EID: 84878829035     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2013.03.021     Document Type: Editorial

References (84)

1. Morley J.E., Kaiser F.E., Perry H.M., et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997, 46:410-413.
2. Perry H.M., Miller D.K., Patrick P., Morley J.E. Testosterone and leptin in older African-American men: Relationship to age, strength, function, and season. Metabolism 2000, 49:1085-1091.
3. Wang C., Nieschlag E., Swerdloff R.S., et al. ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009, 12:5-12.
4. Thomas J.L., Quang B.T., Ochsenbein E., Vincent J.P. Relationship between some biological parameters and plasma testosterone in institutionalized aging men. J Nutr Health Aging 2003, 7:437-439.
5. Abbassi A., Mattson D.E., Cuisinier M., et al. Hyposomatomedinemia and hypogonadism in hemiplegic men who live in nursing homes. Arch Phys Med Rehabil 1994, 75:594-599.
6. Morley J.E., Melmed S. Gonadal dysfunction in systemic disorders. Metabolism 1979, 28:1051-1073.
7. Breuer B., Trungold S., Martucci C., et al. Relationships of sex hormone levels to dependence in activities of daily living in the frail elderly. Maturitas 2001, 39:147-159.
8. Abbassi A.A., Rudman D., Wilson C.R., et al. Observations on nursing home residents with a history of hip fracture. Am J Med Sic 1995, 310:229-234.
9. Drinka P., Jaschob K., Schultz S., Rudman D. Is male hip fracture a marker for low testosterone in elderly male nursing home residents?. J Am Geriatr Soc 1993, 41:192.
10. Ucak S., Basat O., Karatemiz G. Functional and nutritional state in elderly men with compensated hypogonadism. J Am Med Dir Assoc 2013, 14:433-436.
11. Morley J.E. Anorexia, weight loss, and frailty. J Am Med Dir Assoc 2010, 11:225-228.
12. Abellan van Kan G., Rolland Y.M., Morley J.E., Vellas B. Frailty: Toward a clinical definition. J Am Med Dir Assoc 2008, 9:71-72.
13. Rockwood K., Abeysundera M.J., Mitnitski A. How should we grade frailty in nursing home patients?. J Am Med Dir Assoc 2007, 8:595-603.
14. Hoogendijk E.O., van Hout H.P. Investigating measurement properties of the Groningen Frailty Indicator: A more systematic approach is needed. J Am Med Dir Assoc 2012, 13:757.
15. Peters L.L., Boter H., Buskens E., Slaets J.P. Measurement properties of the Groningen Frailty Indicator in home-dwelling and institutionalized elderly people. J Am Med Dir Assoc 2012, 13:546-551.
16. Morley J.E., Vellas B., Abellan van Kan G., et al. Frailty consensus: A call to action. J Am Med Dir Assoc 2013, 14:392-397.
17. Morley J.E. Anabolic steroids and frailty. J Am Med Dir Assoc 2010, 11:533-536.
18. Morley J.E. Frailty, falls, and fractures. J Am Med Dir Assoc 2013, 14:149-151.
19. Von Haehling S., Morley J.E., Anker S.D. From muscle wasting to sarcopenia and myopenia: Update 2012. J Cachexia Sarcopenia Muscle 2012, 3:213-217.
20. Landi F., Liperoti R., Fusco D., et al. Sarcopenia and mortality among older nursing home residents. J Am Med Dir Assoc 2012, 13:121-126.
21. Fielding R.A., Vellas B., Evans W.J., et al. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011, 12:249-256.
22. Roman D., Mahoney K., Mohamadi A. Sarcopenia: What's in a name?. J Am Med Dir Assoc 2013, 14:80-82.
23. Cesari M., Vellas B. Sarcopenia: A novel clinical condition or still a matter for research?. J Am Med Dir Assoc 2012, 13:766-767.
24. Bauer J.M., Kaiser M.J., Sieber C.C. Sarcopenia in nursing home residents. J Am Med Dir Assoc 2008, 9:545-551.
25. Rolland Y., Lauwers-Cances V., Cristini C., et al. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: The EPIDOS (EPIDemiologie de l'OSteoporose) Study. Am J Clin Nutr 2009, 89:1895-1900.
26. Baumgartner R.N., Waters D.L., Gallagher D., et al. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999, 107:123-136.
27. Chu L.W., Tam S., Kung A.W., et al. Serum total and bioavailable testosterone levels, central obesity, and muscle strength changes with aging in healthy Chinese men. J Am Geriatr Soc 2008, 56:1286-1291.
28. Bhasin S. Testosterone supplementation for aging-associated sarcopenia. J Gerontol A Biol Sci Med Sci 2003, 58:1002-1008.
29. Morley J.E., Kaiser F., Raum W.J., et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: Progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci U S A 1997, 94:7537-7542.
30. Chu L.W., Tam S., Lee P.W., et al. Bioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older men. Clin Endocrinol (Oxf) 2008, 68:589-598.
31. Chu L.W., Tam S., Wong R.L., et al. Bioavailable testosterone predicts a lower risk of Alzheimer's disease in older men. J Alzheimers Dis 2010, 21:1335-1345.
32. Morley J.E., Armbrecht H.J., Farr S.A., Kumar V.B. The senescence accelerated mouse (SAMP8) as a model for oxidative stress and Alzheimer's disease. Biochim Biophys Acta 2012, 1822:650-656.
33. Morley J.E., Farr S.A., Kumar V.B., Armbrecht H.J. The SAMP8 mouse: A model to develop therapeutic interventions for Alzheimer's disease. Curr Pharm Des 2012, 18:1123-1130.
34. Kumar V.B., Farr S.A., Flood J.F., et al. Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides 2000, 21:1769-1775.
35. Morley J.E. The SAMP8 mouse: A model of Alzheimer disease?. Biogerontology 2002, 3:57-60.
36. Flood J.F., Farr S.A., Kaiser F.E., et al. Age-related decrease of plasma testosterone in SAMP8 mice: Replacement improves age-related impairment of learning and memory. Physiol Behav 1995, 57:669-673.
37. Cummings-Vaughn L.A., Malmstrom T.K., Morley J.E., Miller D.K. Testosterone is not associated with mortality in older African-American males. Aging Male 2011, 14:132-140.
38. Laughlin G.A., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008, 93:68-75.
39. Araujo A.B., Kupelian V., Page S.T., et al. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 2007, 167:1252-1260.
40. Shores M.M., Matsumoto A.M., Sloan K.L., Kivlahan D.R. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006, 166:1660-1665.
41. Shores M.M., Smith N.L., Forsberg C.W., et al. testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012, 97:2050-2058.
42. McKinney J.D., Bailey B.A., Garrett L.H., et al. Relationship between vitamin D status and ICU outcomes in veterans. J Am Med Dir Assoc 2011, 12:208-211.
43. Demontiero O., Herrmann M., Duque G. Supplementation with vitamin D and calcium in long term care residents. J Am Med Dir Assoc 2011, 12:190-194.
44. Gau J.T. Prevalence of vitamin D deficiency/insufficiency practice patterns in nursing homes. J Am Med Dir Assoc 2010, 11:296.
45. Morley J.E., Argiles J.M., Evans W.J., et al. Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc 2010, 11:391-396.
46. Drinka P.J., Krause P.F., Nest L.J., Goodman B.M. Determinants of vitamin D levels in nursing home residents. J Am Med Dir Assoc 2007, 8:76-79.
47. Morley J.E. Should all long term care residents receive vitamin D?. J Am Med Dir Assoc 2007, 8:69-70.
48. Islam T., Peiris P., Copeland R.J., et al. Vitamin D: Lessons from the veterans population. J Am Med Dir Assoc 2011, 12:257-262.
49. Morley J.E. Vitamin D redux. J Am Med Dir Assoc 2009, 10:591-592.
50. Tajar A., Lee D.M., Pye S.R., et al. The association of frailty with serum 25-hydroxyvitamin D and parathyroid hormone levels in older European men. Age Ageing 2013, 42:352-359.
51. Peterson A., Mattek N., Clemons A., et al. Serum vitamin D concentrations are associated with falling and cognitive function in older adults. J Nutr Health Aging 2012, 16:898-901.
52. Holick M.F. Vitamin D: Extraskeletal health. Rheum Dis Clin North Am 2012, 38:141-160.
53. Morley J.E., Perry H.M., Kaiser F.E., et al. Effects of testosterone replacement therapy in old hypogonadal males: A preliminary study. J Am Geriatr Soc 1993, 41:149-152.
54. Sih R., Morley J.E., Kaiser F.E., et al. Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial. J Clin Endocrinol Metab 1997, 82:1661-1667.
55. Wittert G.A., Chapman I.M., Haren M.T., et al. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 2003, 58:618-625.
56. Bhasin S., Storer T.W., Berman N., et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996, 335:1-7.
57. Haren M.T., Siddiqui A.M., Armbrecht H.J., et al. Testosterone modulates gene expression pathways regulating nutrient accumulation, glucose metabolism and protein turnover in mouse skeletal muscle. Int J Androl 2011, 34:55-68.
58. Sinha-Hikim I., Cornford M., Gaytan H., et al. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metab 2006, 91:3024-3033.
59. Page S.T., Amory J.K., Bowman F.D., et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005, 90:1502-1510.
60. Amory J.K., Watts N.B., Easley K.A., et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrniol Metab 2004, 89:503-510.
61. Srinivas-Shankar U., Roberts S.A., Connolly M.J., et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: A randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010, 95:639-650.
62. Basaria S., Coviello A.D., Travison T.G., et al. Adverse events associated with testosterone administration. N Engl J Med 2010, 363:109-122.
63. Kenny A.M., Kleppinger A., Annis K., et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 2010, 58:1134-1143.
64. Malkin C.J., Pugh P.J., West J.N., et al. Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. Eur Heart J 2006, 27:57-64.
65. Caminiti G., Volterrani M., Iellamo F., et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: A double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009, 54:919-927.
66. Chapman I.M., Visvanathan R., Hammond A.J., et al. Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr 2009, 89:880-889.
67. Cermak N.M., de Groot L.C., van Loon L.J. Perspective: Protein supplementation during prolonged resistance type exercise training augments skeletal muscle mass and strength gains. J Am Med Dir Assoc 2013, 14:71-72.
68. Paddon-Jones D. Perspective: Exercise and protein supplementation in frail elders. J Am Med Dir Assoc 2013, 14:73-74.
69. Tieland M., Dirks M.L., van der Zwaluw N., et al. Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: A randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc 2012, 13:713-719.
70. Tieland M., van de Rest O., Dirks M.L., et al. Protein supplementation improves physical performance in frail elderly people: A randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc 2012, 13:720-726.
71. Singh N.A., Quine S., Clemson L.M., et al. Effects of high-intensity progressive resistance training and targeted multidisciplinary treatment of frailty on mortality and nursing home admissions after hip fracture: A randomized controlled trial. J Am Med Dir Assoc 2012, 13:24-30.
72. Chala E.J., Hayek M.E., Morley J.E. Testosterone replacement therapy and cardiovascular risk factors modification. Aging Male 2011, 14:83-90.
73. Morley J.E. Should frailty be treated with testosterone?. Aging Male 2011, 14:1-3.
74. Morley J.E., Perry H.M. Androgens and women at the menopause and beyond. J Gerontol A Biol Sci Med Sci 2003, 58:M409-M416.
75. Davis S.R. The therapeutic use of androgens in women. J Steroid Biochem Mol Biol 1999, 69:177-184.
76. Dobs A.S., Nguyen T., Pace C., Roberts C.P. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab 2002, 87:1509-1516.
77. Iellamo F., Volterrani M., Caminiti G., et al. Testosterone therapy in women with chronic heart failure: A pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010, 56:1310-1316.
78. Narayanan R., Mohler M.L., Bohl C.E., et al. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal 2008, 6:e010.
79. Dalton J.T., Barnette K.G., Bohl C.E., et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: Results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011, 2:153-161.
80. Hajjar R.R., Kaiser F.E., Morley J.E. Outcomes of long-term testosterone replacement in older hypogonadal males: A retrospective analysis. J Clin Endocrinol Metab 1997, 82:3793-3796.
81. Morley J.E. Androgens and aging. Maturitas 2001, 38:61-71.
82. Nieschlag E., Swerdloff R., Behre H.M., et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Andrology 2006, 27:135-137.
83. Bassil N., Morley J.E. Late-life onset hypogonadism: A review. Clin Geriatr Med 2010, 26:197-222.
84. Tolson D., Rolland Y., Andrieu S., et al. The International Association of Gerontology and Geriatrics/World Health Organization/Society Française de Gérontologie et de Gériatrie Task Force. International Association of Gerontology and Geriatrics: A global agenda for clinical research and quality of care in nursing homes. J Am Med Dir Assoc 2011, 12:184-189.